Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIFA II: Indobufen vs Aspirin in Atrial Fibrillation
NCT00244426Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2000
- Primary completion
- Apr 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Indobufen in Atrial fibrillation (AFib) (2 arms), sponsored by Pfizer. Primary endpoint: Combined endpoints: cerebral ictus, cardiovascular death, nonfatal AMI, or peripheral embolism at 3.5 years. Started Dec 2000; status: completed.
02
Drugs
Indobufen
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00244426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00244426.